Evidence map›Paper›PMID 25449649›Full record

ReviewBiochimica et biophysica acta2015

The isoprostanes--25 years later.

Ginger L Milne, Qi Dai, L Jackson Roberts

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 2 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 2 syntheses or guidelines pooled it, 322 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Plasma FThe Journal of nutrition · 2017
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Rationale and design of the RISE-HF trial: sucrosomial iron in heart failure.International journal of cardiology. Heart & vasculature · 2026
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ginger L MilneDivision of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Qi DaiDivision of Epidemiology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
L Jackson RobertsDivision of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Vanderbilt University · US

Funding

Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI POWERS, ALVIN C · 1986 to 2011
$28.1M
Structural Biology Facility CoreP30ES000267 · NIEHS · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 1985 to 2014
$20.3M
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATIONP50GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 1985 to 2010
$15.0M
Therapeutic Modulation of Endothelial Cell TetrahydrobiopterinP01GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI ROBERTS, JACKSON L · 2011 to 2015
$9.5M
Oxidative Stress, Antioxidants and Breast Cancer RiskR01CA106591 · NCI · VANDERBILT UNIVERSITY · PI DAI, QI · 2004 to 2007
$973k
NCI NIH HHS CA106591NCI NIH HHS R01 CA106591NIDDK NIH HHS DK020593NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P60 DK020593NIEHS NIH HHS ES000267NIEHS NIH HHS P30 ES000267NIGMS NIH HHS GM15431NIGMS NIH HHS P01 GM015431NIGMS NIH HHS P50 GM015431
6 · The paper itself

Abstract

Isoprostanes (IsoPs) are prostaglandin-like molecules generated independent of the cyclooxygenase (COX) by the free radical-induced peroxidation of arachidonic acid. The first isoprostane species discovered were isomeric to prostaglandin F2α and were thus termed F2-IsoPs. Since the initial discovery of the F2-IsoPs, IsoPs with differing ring structures have been identified as well as IsoPs from different polyunsaturated fatty acids, including eicosapentaenoic acid and docosahexanenoic acid. The discovery of these molecules in vivo in humans has been a major contribution to the field of lipid oxidation and free radical research over the course of the past 25 years. These molecules have been determined to be both biomarkers and mediators of oxidative stress in numerous disease settings. This review focuses on recent developments in the field with an emphasis on clinical research. Special focus is given to the use of IsoPs as biomarkers in obesity, ischemia-reperfusion injury, the central nervous system, cancer, and genetic disorders. Additionally, attention is paid to diet and lifestyle factors that can affect endogenous levels of IsoPs. This article is part of a Special Issue entitled "Oxygenated metabolism of PUFA: analysis and biological relevance."

Indexed as

Oxidative StressSignal TransductionAnimalsBiomarkersDiseaseHumansIsoprostanesLipid PeroxidationMolecular StructureStructure-Activity RelationshipBiomarkersIsoprostanesBiomarkerIsoprostaneLipid peroxidationMass spectrometryOxidative stress

Identifiers

PMID25449649
PMCPMC5404383
OpenAlexW2059867409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.